GI Innovation Inc
KOSDAQ:358570
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
8 970
24 000
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
GI Innovation Inc
Accrued Liabilities
GI Innovation Inc
Accrued Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
G
|
GI Innovation Inc
KOSDAQ:358570
|
Accrued Liabilities
₩851m
|
CAGR 3-Years
193%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Accrued Liabilities
₩205.7B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
SK Bioscience Co Ltd
KRX:302440
|
Accrued Liabilities
₩19.7B
|
CAGR 3-Years
20%
|
CAGR 5-Years
34%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hugel Inc
KOSDAQ:145020
|
Accrued Liabilities
₩2.2B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
|
P
|
PharmaResearch Co Ltd
KOSDAQ:214450
|
Accrued Liabilities
₩1.4B
|
CAGR 3-Years
28%
|
CAGR 5-Years
31%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Accrued Liabilities
₩466.4m
|
CAGR 3-Years
23%
|
CAGR 5-Years
42%
|
CAGR 10-Years
N/A
|
|
GI Innovation Inc
Glance View
GI Innovation, Inc. engages in the development of biopharmaceutical products. The company is headquartered in Seoul, Seoul and currently employs 88 full-time employees. The company went IPO on 2023-03-30. The firm is engaged in the business of generating revenue through license fees by technology transfer of new drug candidates in pre-clinical and early clinical stages. The core new drug pipeline includes products such as GI-101 immuno-oncology and GI-301 allergy treatment.
See Also
What is GI Innovation Inc's Accrued Liabilities?
Accrued Liabilities
851m
KRW
Based on the financial report for Dec 31, 2023, GI Innovation Inc's Accrued Liabilities amounts to 851m KRW.
What is GI Innovation Inc's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 3Y
193%
Over the last year, the Accrued Liabilities growth was 21%. The average annual Accrued Liabilities growth rates for GI Innovation Inc have been 193% over the past three years .
You don't have any saved screeners yet
